Study to Evaluate Clinical Efficacy and Safety of Nuvastaticâ„¢ - C5OSEW5050ESA in Diabetic Retinopathy.
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Natureceuticals Sdn Bhd
- Target Recruit Count
- 100
- Registration Number
- NCT04552600
- Locations
- 🇮🇳
Fifepoint Multispeciality Hospital Pvt. Ltd., Pune, Maharashtra, India
Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
Phase 2
Completed
- Conditions
- AstheniaCancer
- Interventions
- Other: Nuvastatic TM (C5OSEW5050ESA) 1000 mg
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Natureceuticals Sdn Bhd
- Target Recruit Count
- 110
- Registration Number
- NCT04546607
- Locations
- 🇮🇳
Notrox Research Pvt Ltd, Bangalore, Karnataka, India
To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Natureceuticals Sdn Bhd
- Target Recruit Count
- 10
- Registration Number
- NCT04542447
- Locations
- 🇮🇳
Navin Hospital, Ghaziabad, Uttar Pradesh, India
© Copyright 2025. All Rights Reserved by MedPath